MAPS / Lykos Therapeutics

Rule Changes

Pursuing revised MDMA therapy application after 2024 FDA rejection

For 55 years, the federal government classified psilocybin, MDMA, LSD, and ibogaine as Schedule I substances — drugs with no accepted medical use. On April 18, 2026, President Trump signed an executive order directing the Food and Drug Administration (FDA) to issue new guidance expediting clinical trials of those same substances for treating post-traumatic stress disorder (PTSD) in veterans, made $50 million in federal funding available for state-level ibogaine research, and opened a pathway for seriously ill patients to access psychedelics under the Right to Try law.

Updated 4 hours ago